Natera, Inc. is a leading global provider of genetic testing and diagnostics, specializing in non-invasive prenatal testing (NIPT), oncology, and organ transplantation.
The company leverages advanced cell-free DNA technology to deliver accurate and reliable genetic insights, helping patients and healthcare providers make informed decisions. Natera’s flagship product, Panorama, is a widely recognized non-invasive prenatal test that screens for chromosomal abnormalities in fetuses as early as nine weeks into pregnancy.
In the oncology space, Natera offers Signatera, a personalized, tumor-informed test that detects minimal residual disease (MRD) and monitors for cancer recurrence. The company also provides Prospera, a test designed to assess organ transplant rejection with a high degree of sensitivity and specificity. Natera’s growth is driven by continuous innovation, expansion of its product offerings, and strategic partnerships with healthcare providers and institutions worldwide.
With a commitment to advancing precision medicine, Natera aims to transform how genetic testing is utilized in prenatal care, oncology, and transplant medicine, ultimately improving patient outcomes and quality of life.
